Don Webber

Chief Executive Officer

A seasoned executive who joined Bridge to Life in January 2022, Don has a proven track record and excels in spearheading companies through diverse and challenging business environments. Specializing in strategic planning and execution across startups, turnarounds, and high-growth scenarios, Don’s leadership style is characterized by a hands-on approach and a relentless drive for results. Having held leadership positions in both small startups and large corporations, Don possess a deep understanding of business dynamics and a keen ability to drive innovation and sustainable growth. With extensive experience spanning various sectors including cardiology, thoracic surgery, biologics, and robotics, Don has consistently delivered exceptional outcomes, and has already advanced Bridge to Life in his two-year leadership tenure.
Notable accomplishments include CEO of SynCardia Systems, LLC, which led to a successful turnaround and sale of the company, highlighted by impactful restructuring and strategic initiatives. His management experience includes Novoste, Ekos, Abiomed, CR Bard and Cordis Corporation. Don also served in the United States Air Force and received his bachelor’s degree in Industrial Engineering Technology from the State University of New York and MBA from Nova Southeastern University.
Committed to knowledge sharing, Don actively engages in teaching and speaking engagements worldwide.

Bob Beechy

Chief Financial Officer

Bob Beechey holds a BS in Economics from Wharton and an MBA from INSEAD. He has over 20 years of experience in senior leadership roles at life sciences companies, including Aspira Women’s Health, ThermoFisher Scientific, and Quintiles.

Jayan Nagendran, MD, PhD, FRCSC

Chief Medical Officer

Dr. Jayan Nagendran is a Cardiac Surgeon and Scientist with a MD and PhD from the University of Alberta. He completed a Cardiothoracic Transplantation surgical fellowship at Stanford University and is currently the Director of Cardiac Surgery and Surgical Director of Lung Transplantation at the University of Alberta. He is also the co-founder of Tevosol.

Blago Herrera

Vice President, Operations

Blago Herrera is a medtech veteran with over 30 years of experience in the industry, including roles at Johnson and Johnson, Abiomed, Novoste Corporation, and most recently, held the title VP of Quality at SynCardia Systems. He has expertise in manufacturing, supply chain, quality, and regulatory affairs, and has built several manufacturing facilities from the ground up.

Aaron Gilchrist

Vice President of Sales, North America

Aaron Gilchrist holds a BS in Finance and Management and has nearly 20 years of experience in the creation and commercialization of medical devices. He has a strong track record of economic development, including the recruitment of Bridge to Life to South Carolina and introducing the company in global markets.

Baha El Mahgoub

Vice President of Sales, International

Baha El Mahgoub holds a BSc in Clinical Pharmacy and has over 20 years of business management experience in the pharmaceutical and medical equipment industries. He has expertise in building and expanding early-stage companies in international markets, with a focus on sales, marketing, and service operations.

Jennifer Guzman

Director, Marketing

Jennifer Guzman has 30 years of experience across MedTech including biotech, diagnostics and healthcare systems. Recently Jennifer served as Vice President of Marketing at Vital Therapies where she led all commercialization activities for a combination orphan cellular therapy device for acute liver failure. Jennifer earned her bachelor’s degree from the University of California at San Diego, and an MBA with a marketing specialization from San Diego State University.

Mauricio Carvalho

Director, Medical & Scientific Affairs

Mauricio Carvalho is a BSN, RN, MBA with advanced degrees in Critical Care Nursing and Dialysis. He has 25 years of clinical experience and has co-authored multiple peer-reviewed publications on Ex Vivo Organ Perfusion. He has held positions at Vital Therapies Inc. and Aerogen Inc.

Chriss Stanford

Director of Clinical Affairs

Chriss Stanford holds a BA and MA in the medical sciences and has over 20 years of experience in clinical research and development, including his prior role at Terumo BCT. He has expertise in clinical operations, regulatory affairs and data management, analysis and reporting through all phases of medical device, pharmaceuticals, and combination products development.

Board

Steve Schweighardt, Chairman

Steve Schweighardt brings over 45 years of industry experience to his role as Chairman of the Board at Bridge to Life. As a founder of Bridge to Life, Steve has been instrumental in driving the company’s mission and strategic vision. Prior to joining Bridge to Life, Steve held key commercial roles at Searle and Cole & Associates, where he honed his leadership and business acumen. His extensive experience and dedication to the industry make him a vital asset to the organization’s continued success.

Don Webber

A seasoned executive who joined Bridge to Life in January 2022, Don has a proven track record and excels in spearheading companies through diverse and challenging business environments. Specializing in strategic planning and execution across startups, turnarounds, and high-growth scenarios, Don’s leadership style is characterized by a hands-on approach and a relentless drive for results. Having held leadership positions in both small startups and large corporations, Don possess a deep understanding of business dynamics and a keen ability to drive innovation and sustainable growth. With extensive experience spanning various sectors including cardiology, thoracic surgery, biologics, and robotics, Don has consistently delivered exceptional outcomes, and has already advanced Bridge to Life in his two-year leadership tenure.
Notable accomplishments include CEO of SynCardia Systems, LLC, which led to a successful turnaround and sale of the company, highlighted by impactful restructuring and strategic initiatives. His management experience includes Novoste, Ekos, Abiomed, CR Bard and Cordis Corporation. Don also served in the United States Air Force and received his bachelor’s degree in Industrial Engineering Technology from the State University of New York and MBA from Nova Southeastern University.
Committed to knowledge sharing, Don actively engages in teaching and speaking engagements worldwide.

David Gill

Currently, Mr. Gill serves on the boards of two public companies: Y-mAbs Therapeutics (YMAB), an immuno-oncology company focused on pediatric brain cancer, and Evolus (EOLS), an aesthetics company. In addition, he serves on the boards of several private companies including as the Chairman of Healthtronics, Inc, a mobile surgical equipment company. Mr. Gill’s other private company boards include RapidPulse, Inc., an ischemic stroke medical device company, Bridge to Life Ltd, a leading company in the organ transplantation market and Perimetrics AI, a dental diagnostic company.
In his most recent operating role Mr. Gill joined Endochoice (NYSE: GI) in August 2014 as CFO, executed its IPO in June 2015, and then later assumed the added roles of President and Chief Operating Officer in March 2016. EndoChoice was a 500-employee public medical device company with operations in US, Germany and Israel. Boston Scientific acquired Endochoice in November 2016, at which point Mr. Gill retired.
Earlier in his career Mr. Gill served in a variety of senior leadership roles (president, COO and CFO) for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Novoste Corporation and Dornier Medical.
Mr. Gill has led the IPO’s of four companies, has sold four public companies, and has raised more than $1.3 Billion in equity and debt during his career. He graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned an MBA (with distinction) from Emory University.

Brian Lenz

Mr. Lenz is the Executive Vice President, Chief Financial Officer of ADMA Biologics and General Manager of the Company’s subsidiary business unit. Mr. Lenz joined ADMA in May 2012 and was instrumental in preparing the Company’s IPO and listing on the NASDAQ in October 2013. In 2017, Mr. Lenz co-led the acquisition of the Company’s contract manufacturer. As part of this acquisition, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resources activities and information technology systems during and after the transaction. Mr. Lenz’s financial and operational leadership experience includes completing numerous capital markets equity financings, negotiating multiple significant credit facilities, leading strategic transactions, licensing and collaboration arrangements throughout his 25-year career, serving both public and private companies in the life sciences and medical device sectors. He leads ADMA’s investor relations efforts and continues to oversee the Company’s SEC financial reporting and SOX compliance activities amongst other operational duties.
Prior to joining ADMA, Mr. Lenz was at CorMedix Inc., a developmental-stage pharmaceutical and medical device company, where he held the position of Chief Financial Officer from February 2010 to May 2012 and Chief Operating Officer and Chief Financial Officer from January 2012 to May 2012. Prior to joining CorMedix, Mr. Lenz served as Chief Financial Officer of Arno Therapeutics, Inc. from July 2008 to February 2010, Chief Financial Officer of VioQuest Pharmaceuticals, Inc. from April 2004 to June 2008, Controller of Chiral Quest, Inc., a subsidiary of VioQuest Pharmaceuticals, from October 2003 to March 2004, Controller of Smiths Detection from July 2000 to October 2003, and senior auditor at KPMG LLP from October 1998 to July 2000.
Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.
Mr. Lenz is the finance committee co-chairperson for BioNJ. He has actively been involved in advising biotechs, pharmaceutical companies, venture capitalists, debt lenders and hedge funds.
Mr. Lenz has received multiple awards for his various accomplishments as CFO, which include: Best Growth Manager, Financier of the Year, Public Company and Capital Success.

Sam Chawla

Sam Chawla has over 18 years of experience in healthcare corporate finance and is a member of the investment committee for the credit opportunities funds at Perceptive. Prior to joining Perceptive in 2013, he was Managing Director in the Global Healthcare Group at UBS Investment Bank. Sam has in-depth experience in M&A advisory, underwriting debt and equity financings across healthcare.He graduated from Johns Hopkins University with a B.A. in Economics and from Georgetown University with a MBA. Sam currently serves as a member on the Dean’s Advisory Board for the Krieger School of Arts & Sciences at Johns Hopkins University.

Dr. Darren Freed

Dr. Darren Freed is a cardiac surgeon clinician-scientist with an interest in heart and lung failure and novel techniques to treat these conditions. His primary clinical interests are in cardiothoracic transplantation and mechanical circulatory assistance as well as less invasive cardiac surgery and congenital cardiac surgery. His primary research interests are in ex vivo organ perfusion, heart and lung transplantation and mechanical circulatory support. He obtained his MD from the University of Alberta in 1998 and completed his cardiac surgical training at the University of Manitoba where he also obtained a PhD in Physiology. In 2007 he completed a Clinical Fellowship in Cardiothoracic Transplantation and Ventricular Assist Devices at Papworth Hospital in Cambridge, United Kingdom. He is currently a Professor, Division of Cardiac Surgery, Department of Surgery, University of Alberta, with cross appointments in the Departments of Physiology and Biomedical Engineering. He has authored over 180 peer-reviewed manuscripts and has held numerous peer-reviewed grants in support of his research. He has over 50 patents world-wide, and in 2014 he founded Tevosol, Inc, to commercialize organ perfusion technology developed in his laboratory. In 2020, Tevosol merged with Bridge to Life to become a dominant player in the field of organ recovery, preservation and transplantation.